Donaldson Capital Management LLC Has $817,000 Stock Holdings in Stryker Co. (NYSE:SYK)

Donaldson Capital Management LLC trimmed its position in shares of Stryker Co. (NYSE:SYK) by 8.0% during the first quarter, HoldingsChannel.com reports. The firm owned 2,194 shares of the medical technology company’s stock after selling 190 shares during the period. Donaldson Capital Management LLC’s holdings in Stryker were worth $817,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Stryker during the fourth quarter valued at about $25,000. Capital A Wealth Management LLC acquired a new stake in shares of Stryker during the fourth quarter valued at about $26,000. Rakuten Securities Inc. boosted its stake in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC acquired a new stake in shares of Stryker during the fourth quarter valued at about $30,000. Finally, BankPlus Trust Department acquired a new stake in shares of Stryker during the fourth quarter valued at about $33,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SYK has been the topic of a number of recent analyst reports. Wall Street Zen lowered Stryker from a “buy” rating to a “hold” rating in a research note on Friday, June 6th. Truist Financial lifted their price objective on Stryker from $390.00 to $400.00 and gave the stock a “hold” rating in a research note on Monday, May 5th. Evercore ISI cut their price objective on Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a research note on Friday, May 2nd. The Goldman Sachs Group set a $422.00 price objective on Stryker in a research note on Tuesday, March 4th. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Monday, May 5th. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $427.30.

Stryker Stock Down 1.0%

Shares of NYSE SYK opened at $381.03 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The stock has a market capitalization of $145.43 billion, a PE ratio of 49.10, a P/E/G ratio of 2.93 and a beta of 0.91. The business’s fifty day moving average price is $371.23 and its 200-day moving average price is $375.95.

Stryker (NYSE:SYK) last released its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.73 by $0.11. The company had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period in the previous year, the company posted $2.50 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be paid a $0.84 dividend. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. Stryker’s dividend payout ratio is currently 45.41%.

Insiders Place Their Bets

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.